ASH 2021 | Trends in AML and MDS at ASH 2021
Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, comments on key topics in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) to be discussed at the ASH 2021 annual meeting. In the MDS space, Dr Sekeres highlights reports of IDH inhibitor use as single agents in patients with IDH1/2 mutations, as well as a number of studies of combination therapy. For AML, several studies have investigated triplet combinations with a backbone of venetoclax plus azacitidine, decitabine, or low-dose cytarabine. Dr Sekeres also comments on abstracts discussing menin inhibitors and venetoclax plus FLAG-IDA. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
My specialty is myelodysplastic syndromes and acute myeloid Leukemia. Within myelodysplastic syndromes I’ve noticed some trends this year. There are some reports on using IDH inhibitors, both ivosidenib and enasidenib as single agents in patients who have IDH one or IDH two mutations. There are also a series of abstracts on combination therapies. I’ll be presenting the results of the PANTHER trial which was a large, 450 patient randomized study in higher-risk MDS, CMML and oligoblastic leukemia of patients receiving azacitidine and pevonedistat versus azacitidine alone...
My specialty is myelodysplastic syndromes and acute myeloid Leukemia. Within myelodysplastic syndromes I’ve noticed some trends this year. There are some reports on using IDH inhibitors, both ivosidenib and enasidenib as single agents in patients who have IDH one or IDH two mutations. There are also a series of abstracts on combination therapies. I’ll be presenting the results of the PANTHER trial which was a large, 450 patient randomized study in higher-risk MDS, CMML and oligoblastic leukemia of patients receiving azacitidine and pevonedistat versus azacitidine alone. We’ll also see a bunch of presentations on combinations of azacitidine and venetoclax, both for the upfront treatment of patients with higher-risk MDS and in the relapsed/refractory setting. Finally, we’ll be seeing a presentation of the addition of molecular markers to the revised international prognostics scoring system. Now within acute leukemia, the trends I’ve noticed are also with combinations, but AML is a little further along than MDS.
So we’re going to be seeing a lot of presentations on triplet combinations with a backbone of venetoclax, plus either azacitidine or decitabine or low dose cytarabine. We’re seeing the addition of drugs like cusatuzumab, which is an anti-CD7 monoclonal antibody magrolimab, an anti-CD47 monoclonal antibody, IMGN 632, an anti-CD123 monoclonal antibody and FLT3 inhibitors like gilteritinib for patients who have AML with FLT3 positivity. We’re also seeing menin inhibitors in patients with MLL and NPM1. And we’re seeing the combination of venetoclax with FLAG-Ida for a more intensive combination approach. So lots to look forward to, I think in myeloid malignancies, focusing on myelodysplastic syndromes and acute myeloid leukemia.
Read more...
